Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, June 2006, p. 702-703, Vol. 13, No. 6
1071-412X/06/$08.00+0 doi:10.1128/CVI.00194-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Edith Kassa,1
Germain Zandanga,1
Yves-Brillant Service,2
Albert Ignaleamoko,3 and
Antoine Talarmin1*
Institut Pasteur de Bangui,1 Department of Medicine, Hôpital Communautaire,2 Chest Clinic, National Teaching Hospital, Bangui, Central African Republic3
Received 28 June 2005/ Returned for modification 19 September 2005/ Accepted 22 March 2006
|
|
|---|
|
|
|---|
Study participants were recruited from the Department of Medicine at Bangui Community Hospital and from the Chest Clinic at National Teaching Hospital in Bangui, Central African Republic, between 12 July and 1 September 2004. Eligible participants were suspected PTB cases, defined as patients who had a history of cough lasting
3 weeks and who were identified by a physician as needing an evaluation for TB. Giving of informed consent, age of
18 years, and either sex were considered inclusion criteria for the study. All consecutive suspected PTB patients who fulfilled the inclusion criteria were enrolled and underwent an evaluation that is considered routine for suspected PTB in the Central African Republic. This consisted of providing three sputum specimens for acid-fast bacillus smearing within 48 h of enrollment. In addition, these same sputum specimens and blood samples were processed for mycobacterial culture (3, 5). Blood samples were also used for HIV testing as described elsewhere (8).
The SDHO MTB test (SDHO Laboratories Inc., Canada) utilizes the principle of immunochromatography and is a unique two-site immunoassay on a membrane. As the test sample flows through the membrane assembly of the device, a colored recombinant TB antigen-colloidal gold conjugate complexes with anti-TB antibodies in the sample. This complex moves through the membrane to the test region, where it is immobilized by the recombinant TB antigen coating of the membrane, leading to formation of a colored band which confirms a positive test result. The absence of this colored band in the test region indicates a negative test result. The unreacted conjugate and unbound complex, if any, move further on the membrane along with rabbit immunoglobulin G (IgG) in the colloidal gold conjugate and are subsequently immobilized by goat anti-rabbit antibodies on the membrane at the control region, forming a pink band. This control band serves to validate the test results. In our laboratory, the test was performed with 50 microliters of blood serum specimens as soon as possible on the day of collection. The results were interpreted after 15 min of migration, according to the instructions of the manufacturer.
Patients were confirmed as having PTB disease on the basis of positive sputum and/or blood culture for Mycobacterium tuberculosis. Sensitivity, specificity, and positive and negative predictive values were assessed for microscopic examination and for the serological test. Chi-square and Yates corrected P values were used for comparisons of performance between these two methods.
A total of 99 suspected PTB patients were included for evaluation during the study period. The median age was 31 years (range, 18 to 72 years), with 53 men and 46 women. Among 98 patients who accepted the HIV serology test, 55 (56.1%) were HIV positive. M. tuberculosis was isolated from 31 (56.4%) of the HIV-positive patients and from 37 (86.0%) of the HIV-negative patients (P < 0.002). The patient who refused HIV testing was culture negative for M. tuberculosis. The sensitivity of sputum smear examination was much lower among HIV-positive PTB patients (21 of 31; 67.7%) than among HIV-negative PTB patients (34 of 37; 91.9%) (P < 0.01). A similar tendency was observed for the SDHO MTB test; the sensitivity was 16.1% (5 of 31) among HIV-positive PTB patients and 32.4% (12 of 37) among HIV-negative PTB patients. However, this difference was not statistically significant (P = 0.12). The overall sensitivity of the SDHO MTB test was only 20.6% (17 of 68), which is much lower than that of sputum smear examination (80.9%; 55 of 68). The specificities of sputum smear examination (100.0%) and the SDHO MTB test (90.3%) were similar (Table 1).
|
View this table: [in a new window] |
TABLE 1. Performances of microscopy examination and the SDHO MTB test with culture-confirmed PTB patients and non-PTB patients in Bangui, Central African Republic
|
The sensitivity of sputum smear examination was much lower among HIV-positive patients than among HIV-negative patients. This is consistent with previous reports (9), and although the reasons are unclear, it could be due in part to the degree of cellular immunocompromise. The likelihood of a positive sputum smear is lower, because inflammation in the lung decreased with the severity of cellular immunocompromise associated with HIV. The same trend was observed with the SDHO MTB test, and this is not surprising because serological tests are not very sensitive in HIV patients (2). However, these results should not preclude further experiments using other commercial serological tests with large groups of TB- and HIV-positive patients to address the observation of low sensitivity.
Despite an acceptable specificity, this novel serological test lacks the sensitivity required to replace the sputum smear microscopy method in our population. Further improvements are needed before this test could be useful in our setting.
We are grateful to the French Association Raoul Follereau for financial support.
This article is dedicated to the memory of our friend and colleague, Eric Kassa-Kelembho, who died on a mission against tuberculosis. His death is a loss to both us and the Central African Republic.
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»